(19)
(11) EP 1 374 899 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(48) Corrigendum issued on:
10.03.2004 Bulletin 2004/11

(43) Date of publication:
02.01.2004 Bulletin 2004/01

(21) Application number: 02705269.5

(22) Date of filing: 15.03.2002
(51) International Patent Classification (IPC)7A61K 45/00, A61K 31/5575, A61P 43/00, A61P 25/00, A61P 25/22
(86) International application number:
PCT/JP2002/002513
(87) International publication number:
WO 2002/076505 (03.10.2002 Gazette 2002/40)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 16.03.2001 JP 2001075398

(71) Applicant: ONO PHARMACEUTICAL CO., LTD.
Osaka-shi, Osaka 541-8526 (JP)

(72) Inventors:
  • NARUMIYA, Shuh
    Kyoto-shi, Kyoto 606-0007 (JP)
  • MARUYAMA, Takayuki, Ono Pharmaceutical Co., Ltd.
    Mishima-gun, Osaka 618-8585 (JP)

(74) Representative: Henkel, Feiler, Hänzel 
Möhlstrasse 37
81675 München
81675 München (DE)

   


(54) REMEDIES FOR POST-TRAUMATIC STRESS DISORDER


(57) The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds(EP1 agonists), which activate EP1 receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP1 agonists such as (13E)-(11 α, 15S, 17S)-2, 5-ethano-6, 9-dioxo-11, 15-dihydro-17, 20-dimethylprosta-13-enoic acid, PGE1, or PGE2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).